Some of the leading pharmaceutical companies are increasing spending on the research and development of next generation vaccines which aim to cure the most common diseases and provide hope to millions as well as allowing them diversify their product portfolio to other parts of the world where there may be a greater need for vaccinations.
Fleming Europe’s conference on Next Generation Vaccines will take place at Hilton in Vienna, Austria on the 24th and 25th February 2011. It will be an opportunity to meet experts in the field. Paneled speakers include Michel Zaffran from WHO and Dr Satish D. Ravetkar from Serum Institute of India, who will be speaking about ideal attributes for vaccines for use in low and middle income countries. Dr Mansour Yaich from PATH will focus on maximizing vaccine accessibility benefits through strategic public - private partnerships, affordability and intellectual property. Together with representatives from four associations as well as world leading pharmaceutical companies such as Merck & Co., Novartis, Pfizer, Abbott Biologicals B.V.
Take part in a pre-conference workshop which will discuss accelerating the development process, consisting of all the crucial parts within the vaccine lifecycle. From research and development, labeling, supply chain management, to marketing strategies, and getting the final product to the end customer.
Industry professionals will also highlight how to prepare and plan for future pandemics. It will be a chance to improve commercial networks and to seek new business opportunities.
Should you decide to become one of the attendees please contact Barbora Kuckova on +421 257 272 126 or email firstname.lastname@example.org